CSIMarket
 
Mallinckrodt Plc  (MNK)
Other Ticker:  
 
 
Price: $0.3402 $-0.06 -14.971%
Day's High: $0.4102 Week Perf: -39.2 %
Day's Low: $ 0.30 30 Day Perf: -79 %
Volume (M): 543 52 Wk High: $ 8.29
Volume (M$): $ 185 52 Wk Avg: $3.01
Open: $0.40 52 Wk Low: $0.30



 Market Capitalization (Millions $) 5
 Shares Outstanding (Millions) 13
 Employees 3,600
 Revenues (TTM) (Millions $) 2,266
 Net Income (TTM) (Millions $) -2,841
 Cash Flow (TTM) (Millions $) -1,021
 Capital Exp. (TTM) (Millions $) 45

Mallinckrodt Plc
Mallinckrodt Plc is a specialty pharmaceutical company that develops and manufactures a wide range of medical products used in the treatment of rare and critical diseases.

The company was founded in 1867 and is headquartered in Dublin, Ireland, with its primary commercial offices located in the United States. With a rich history of over 150 years, Mallinckrodt has become a leading provider of medical products and services in the healthcare industry, serving millions of patients worldwide.

The company's pharmaceutical products cover a range of areas, including pain management, autoimmune and rare diseases, respiratory disorders, and central nervous system disorders. Mallinckrodt is known for producing specialty drugs such as Acthar Gel, a drug used in the treatment of autoimmune disorders, and Ofirmev, an intravenous acetaminophen injection used for pain management in hospitals.

In addition to pharmaceutical products, Mallinckrodt also produces medical devices and diagnostics tools. The company's medical devices line includes products such as surgical instruments, single-use catheters, and implantable devices for spine and orthopedics. Its diagnostics business offers various imaging agents and injectable dyes used in radiology and cardiology procedures.

Mallinckrodt's operations span over 40 countries, with manufacturing facilities located in the Americas, Europe, and Asia. The company employs over 4,500 people and maintains strong partnerships with healthcare providers and researchers.

Mallinckrodt has a strong commitment to social responsibility and sustainability. The company has implemented green initiatives to reduce its environmental footprint, such as carbon emissions reduction targets, waste diversion programs, and water conservation efforts. Furthermore, the company supports various community outreach programs, including those focused on education, health, and the environment.

Overall, Mallinckrodt is a reputable and innovative pharmaceutical company known for its high-quality products and commitment to improving patient care. Its dedication to social responsibility and sustainability has also garnered the company a positive reputation in the healthcare industry.


   Company Address: College Business & Technology Park Dublin 15
   Company Phone Number: 696 0000   Stock Exchange / Ticker: MNK
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Mallinckrodt Plc

Mallinckrodt Plc's Third Quarter Sees Revenue Rise, But Net Losses Paint a Different Picture



Mallinckrodt Plc, a major player in the pharmaceutical industry, recently released its financial results for the third quarter of 2023. The report highlights important figures such as earnings per share, revenue growth, net loss, and inventory levels. This article aims to explain and analyze these figures, comparing them to previous periods and industry peers.
Earnings per Share and Revenue Growth
In Q3 2023, Mallinckrodt Plc experienced a substantial increase in the loss per share compared to the previous year and the previous reporting season. The loss per share rose to $-128.60 from $-21.58 in the same period a year before, and $-56.74 from the previous reporting season.

Mallinckrodt Plc

Surprising Twist: Despite Revenue Surge, Profits Elude Mallinckrodt Plc in Q2 2023 Earnings Season

Mallinckrodt Plc, a major player in the pharmaceutical preparations industry, reported a surge in revenue of 24.027% to $474.90 million in the fiscal time-frame ending June 30, 2023, compared to the previous year. While this increase in revenue may seem positive at first glance, a closer look at the financials reveals concerning trends that suggest the company's prospects may not be as favorable as they appear.
One alarming aspect is the significant increase in the deficit per share, which stands at a staggering $-56.74 per share. This is a sharp rise from the previous period's deficit of $-18.93 per share, indicating a deteriorating financial situation for Mallinckrodt. Furthermore, the company's net deficit for the second quarter of 2023 reached a whopping $-747.800 million, a considerable surge from $-193.500 million in the previous year. These figures raise serious concerns about the company's ability to manage its finances effectively and generate sustainable profits.

Mallinckrodt Plc

Improved Revenue Figures Make Mallinckrodt Plc a Promising Contender, Earning $424.6 Million in Q1 2023

As a journalist, I am interpreting the financial results of Mallinckrodt Plc, a major pharmaceutical company. According to the financial report, the company's ability to collect accounts receivable sequentially worsened to 4.68, which is quite low and points towards a challenging and deteriorating business climate for the industry.
The average receivable collection period for the company in the first quarter of 2023 was 78 days, which is longer than the 76 days reported in the previous quarter of September 2022. This increase is not favorable, as it indicates that the company is taking more time to collect payments from clients.






 

Mallinckrodt Plc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com